Fudan University Shanghai Cancer Center (FUSCC) is ranked #3 for oncology in China and serves as the national reference standard for breast cancer diagnosis and treatment. With over 5,000 cancer surgeries performed annually, 200+ active clinical trials, and multidisciplinary tumour boards that follow NCCN and ESMO international guidelines, FUSCC combines research-level expertise with high surgical volume — for the right case, it may be a genuinely strong option. China Care helps you work out whether FUSCC is a suitable fit for your diagnosis, carries out a Case Investigation on your behalf before you travel, then provides bilingual coordination throughout your stay.
Fudan University Shanghai Cancer Center (FUSCC, 复旦大学附属肿瘤医院) traces its origins to 1931 as China’s first dedicated cancer hospital. Today it is ranked #3 nationally for oncology in the Fudan University Hospital Ranking, holding #1 position in multiple individual cancer specialties — including breast cancer. It is the most intensively benchmarked oncology institution in the country.
FUSCC operates as a fully integrated cancer centre: surgical oncology, medical oncology, radiation therapy, palliative care, and cancer genetics are all housed within a single institution with shared multidisciplinary tumour boards. Every complex case is reviewed by a team that includes surgeons, oncologists, radiologists, and pathologists simultaneously — the approach recommended by NCCN and ESMO guidelines for complex oncology cases.
With over 200 active clinical trials, FUSCC also provides access to investigational agents and novel treatment sequences not available at most hospitals. For patients whose cancer has not responded to standard treatment, or who want access to the latest research protocols alongside established care, FUSCC represents a genuinely compelling alternative to Western oncology centres.
FUSCC is ranked #3 for oncology in China and #1 for breast cancer specifically. Multidisciplinary tumour boards follow NCCN and ESMO international guidelines. When a Chinese oncologist wants a second opinion on a complex breast, lung, or GI cancer case, FUSCC’s recommendations are considered the reference standard. For international patients, this means accessing China’s most rigorous oncological decision-making framework.
Over 5,000 cancer surgeries performed annually across all tumour sites. High surgical volume at a cancer-specific hospital produces consistently superior outcomes compared to general hospital cancer departments. Minimally invasive and robotic-assisted surgery is the default approach for suitable cases. Reconstructive surgery following mastectomy is performed by dedicated plastic surgery teams integrated with the oncology programme.
With over 200 active clinical trials, FUSCC provides access to investigational agents that are 2–5 years from standard availability. Trials span immunotherapy combinations, targeted agents, novel chemotherapy sequences, and precision oncology approaches. For patients who have failed standard therapy or who want trial enrolment alongside conventional treatment, FUSCC’s research infrastructure provides options unavailable at most hospitals globally.
Finding a hospital's name is easy. Knowing whether it's actually the right one for your situation is much harder — that's where China Care helps.
Most international patients researching FUSCC are unsure whether it's genuinely the right fit for their case, or whether another hospital might serve them better. China Care helps you answer questions like:
FUSCC treats all major cancer types within a fully integrated multidisciplinary framework. Below are the specialties most commonly accessed by international patients through China Care.
Finding a hospital is the easy part. Understanding whether it's the right one for your situation is harder — China Care guides you through that, from initial guidance through to on-the-ground support in Shanghai.
China Care coordinates the full intake process for international patients, from initial record submission through to on-the-ground support during your stay in Shanghai.
Share your pathology report, staging imaging (CT, PET-CT, MRI), genetic testing results where available, and a full treatment history. For breast cancer cases, include hormone receptor status (ER, PR, HER2) and any prior surgery or systemic therapy details. China Care prepares a bilingual case summary for the relevant FUSCC department within 1–2 working days.
records review · 1–2 daysIf it makes sense to go further, Case Investigation looks into whether FUSCC is genuinely a suitable option for your case — before you commit to travelling. This includes China Care attending FUSCC in person and, where appropriate, a proxy consultation with the relevant specialist on your behalf. The specialist reviews your case summary, indicates whether treatment is suitable, and gives an initial direction, with the outcome reported back to you and interpreted in real time.
This is a paid service, agreed with you upfront, which covers hospital registration, the in-person proxy consultation, and real-time voice interpretation. Already in China? Skip this step — China Care can arrange direct escort and interpretation for your own visit instead.
case investigation · fixed fee · results same dayArmed with the specialist’s initial direction, you travel to Shanghai for your own in-person consultation at FUSCC. The specialist reviews your case in person, confirms the treatment plan, and issues a formal cost estimate — this step cannot be completed remotely at a public hospital. China Care’s bilingual coordinator accompanies you throughout. For complex or advanced cases, a multidisciplinary tumour board (MDT) discussion may be convened at this stage.
in-person consultation · treatment plan & cost estimate issuedChina Care coordinates your hospital admission through the International Medical Centre. For inpatient surgical treatment, admission occurs on the agreed date. Outpatient treatment (chemotherapy, radiation) can be managed from accommodation near the hospital. China Care’s coordinator remains available throughout your stay for communication support and logistical assistance.
All treatment fees are paid directly to the hospital in Chinese yuan (RMB). FUSCC does not accept international credit cards for inpatient treatment or surgery. A deposit is required at admission; the balance is settled before or at discharge. China Care does not collect or handle medical payments.
IMC admission · RMB payment direct to hospitalFull treatment summary, pathology results, and follow-up recommendations are provided in bilingual form. For patients enrolled in clinical trials, a remote monitoring schedule is established. China Care ensures all documentation is prepared in a format compatible with your home oncologist and arranges any necessary return visit scheduling if continuation of treatment in Shanghai is planned.
bilingual documentation · trial follow-up · post-discharge supportWhichever stage you're at, China Care's role is the same: help you make an informed decision, not just a booking.
Understand your options before travelling — including whether FUSCC or another hospital is a suitable fit for your case.
Learn more →Appointments, interpreters, and hospital coordination once you're ready to move forward.
Learn more →Support before, during, and after treatment in China — from admission through to follow-up care.
Learn more →We'll help you understand whether FUSCC — or another hospital in China — may be a better option for your situation.
China Care coordinates your case with Fudan University Shanghai Cancer Center’s International Medical Centre. Treatment costs are quoted directly by the hospital. We never add to or mark up the hospital’s quoted treatment cost.